← Compound Library

Somatostatin-14

Endogenous Somatostatin

Also known as: SRIF · Somatostatin · Growth Hormone-Inhibiting Hormone

The native 14-amino-acid hypothalamic hormone that inhibits GH, insulin, glucagon, & multiple GI peptides. The parent molecule for all somatostatin analogs.

Typical Dose

Research reference standard only

Route

IV infusion (research)

Cycle

Research use

Half-life

~1–3 minutes

Storage

Lyophilized: 2–8°C. Reconstituted: use immediately.

Overview

Somatostatin-14 is the endogenous cyclic tetradecapeptide produced by the hypothalamus, pancreatic D cells, & GI tract. It inhibits GH release, insulin, glucagon, secretin, gastrin, & multiple other hormones. Its very short half-life of 1–3 minutes limits clinical utility — synthetic analogs (octreotide, lanreotide) are used instead.

Quick Start Guide

1

Not used clinically due to 1–3 minute half-life. See Octreotide or Lanreotide for clinical analogs.

Research Indications

Research reference compound

Research Only

Used as reference for characterizing somatostatin receptor binding & developing synthetic analogs.

Side Effects & Safety

Common

  • Hypoglycemia (rebound after infusion)
  • Hyperglycemia (acute)

When to Stop

  • Hypoglycemia symptoms

How to Reconstitute

1

Research use: reconstitute in physiological buffer immediately before use.

Dosing math: Use immediately after reconstitution — very short stability.

Quality Indicators

Good — use as normal

  • Clear solution

Discard immediately

  • Any discoloration or particulate

Community Insights

Self-reported. Reflects user experience, not clinical outcomes.

Verify what you have

Information on this page applies to pharmaceutical-grade peptides. Purity & identity of research-grade products vary. Certipep provides independent ESI-TOF-MS & HPLC analysis with a signed analytical report.

Submit a sample